Cardiac tamponade induced by dabrafenib and trametinib combination therapy for melanoma: Case report

RATIONALE: BRAF and MEK inhibitors (BRAF/MEKi) are targeted therapy for proto-oncogene BRAF mutated metastatic unresectable melanoma. Compared to monotherapy, an increased cardiovascular toxicity is reported with the combination of Dabrafenib and Trametinib. This case report documents Grade 4 cardia...

Descripción completa

Detalles Bibliográficos
Autores principales: Sundaram, Vinita Ruth, Abbas, Tahir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221704/
https://www.ncbi.nlm.nih.gov/pubmed/30383630
http://dx.doi.org/10.1097/MD.0000000000012751

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6221704/
https://www.ncbi.nlm.nih.gov/pubmed/30383630
http://dx.doi.org/10.1097/MD.0000000000012751

Ejemplares similares